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Abstract We have generated soluble recombinant forms of the 
costimulatory molecules B7-1 and B7-2, and their counter-
receptor CTLA-4 using a yeast Pichia pastoris expression 
system. Fragments comprising the extracellular domains of 
human B7-1, B7-2, and CTLA-4 molecules were expressed at 
high levels and could be purified from culture supernatants 
following a simple one-step purification protocol. The recombi-
nant proteins retained their functionality and specific binding to 
their natural counterparts could be demonstrated by FACS 
analysis. In T cell proliferation assays costimulatory activity of 
immobilized B7-1 and B7-2 proteins in the presence of an anti-
CD3 antibody was observed with the B7-1 protein being more 
potent than B7-2. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
For activation and clonal expansion T cells require costi-
mulatory signals in addition to the primary signal provided by 
the T cell receptor (TCR), which interacts with antigenic pep-
tides in the context of major histocompatibility complex class 
I or II molecules and confers antigen specificity [1]. The sec-
ond, costimulatory signal can be provided by cell surface mol-
ecules on antigen presenting cells such as B7-1 (CD80) and 
B7-2 (CD86) which interact with their counter-receptors on T 
cells [2]. 
CD28 is the major costimulatory signal receptor for CD4+ 
and CD8+ T cells and members of the B7 family are its nat-
ural ligands. TCR and costimulatory signals together induce T 
cell proliferation and the production of cytokines. CTLA-4 
binds to members of the B7 family with approximately 20-
fold higher affinity than CD28, but in contrast to CD28 trans-
mits a negative signal to the T cell which contributes to the 
termination of the T cell response [3,4]. 
B7-1 and B7-2 as well as their counter-receptors CD28 and 
CTLA-4 are transmembrane glycoproteins of the Ig-super-
family [5]. B7-1 and B7-2 are expressed on the cell surface 
as monomeric proteins and carry both an IgC and an IgV 
loop in their extracellular domains [6,7]. Monomeric and di-
sulfide-linked homodimeric forms of CD28 and CTLA-4 pro-
teins which both contain a single extracellular IgV domain 
have been described [8,9]. Soluble fusion proteins consisting 
of the extracellular domains of B7-1, B7-2, or CTLA-4 genet-
*Corresponding author. Fax: (49) (761) 206 1599. 
E-mail : wels@tumorbio.uni-freiburg.de 
ically fused to an IgG Fc region have been produced in mam-
malian cells as tools to study the interaction of costimulatory 
ligands and receptors, and as reagents of potential therapeutic 
value [10]. CTLA-4-Ig fusion protein is a potent inhibitor of T 
cell activation in vitro and in experimental model systems in 
vivo has been shown to prevent autoimmune disease and to 
suppress tissue graft rejection in transplantation experiments 
[11-13]. 
So far only few attempts have been made to utilize non-
mammalian expression systems for the production of lympho-
cyte cell surface antigens [14-17]. Since the majority of lym-
phocyte surface antigens are post-translationally modified 
which might be crucial for their biological activity, expression 
in Escherichia coli has its limitations. In contrast, despite dif-
ferences in the glycosylation machinery of the yeast Pichia 
pastoris and mammalian cells, several heterologous glycopro-
teins have been reported to be readily expressed, correctly 
folded, and glycosylated in P. pastoris yielding biologically 
active proteins [18]. 
Here we have extended the use of the P. pastoris expression 
system to the production of the costimulatory B7-1 and B7-2 
molecules and their counter-receptor CTLA-4. The extracel-
lular domains of human B7-1, B7-2, and CTLA-4 were ex-
pressed at high levels as soluble recombinant proteins and 
purified from culture supernatants following a simple one-
step purification protocol. The yeast-produced molecules re-
tained their functionality in a variety of in vitro assays sug-
gesting P. pastoris as a useful alternative to mammalian sys-
tems for the expression of soluble forms of lymphocyte cell 
surface molecules. 
2. Materials and methods 
2.1. Cell lines and cell culture conditions 
CHO and CHO-CTLA-4 cells (see below) were maintained in 
MEMa with deoxyribonucleosides (Gibco BRL), containing 2 mM 
glutamine, 50 uM ß-mercaptoethanol, 10% heat-inactivated fetal bo-
vine serum (FBS), and 1 mg/ml G418 (CHO-CTLA-4). The acute 
monocytic leukemia cell line THP-1 (ATCC) and B7-l-transfected 
THP-1 cells (kindly provided by A. Lanzavecchia, Basel) were grown 
in RPMI medium supplemented with 2 mM glutamine, 5 mM Na-
pyruvate, 5 mM non-essential amino acids, 50 (iM ß-mercaptoetha-
nol, 10% heat-inactivated FCS, and 1 mg/ml G418 (THP-1-B7-1). The 
P. pastoris GS 115 yeast cells (Invitrogen, Leek, Netherlands) were 
propagated in buffered minimal glycerol-complex medium (BMGY) 
and expression of recombinant proteins was induced in buffered min-
imal methanol-complex medium (BMMY) according to the distribu-
tor's recommendations. 
2.2. Construction of plasmids for the expression of soluble extracellular 
domain of human B7-1 and B7-2 
A cDNA fragment encoding the extracellular domain of human B7-
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1 (amino acid residues 1-208; referred to as B7-l2os) was derived by 
PCR using full-length B7-1 cDNA (kindly provided by U. Zangemeis-
ter-Wittke, Zurich) as a template and the oligonucleotides B7-1-sense 
5'-TATGTCGACGCTAGCGTTATCCACGTGACC-3' and B7-1-
antisense 5'-TATCTCTAGACCATCGATGTTATCAGGAAAATG-
CTCTTGC-3' which introduce Sail and Nhel restriction sites at the 
5'-end and Clal and Xbal restriction sites at the 3'-end of the PCR 
product. Likewise a cDNA fragment encoding the extracellular do-
main of human B7-2 (amino acid residues 1-225; referred to as B7-
2225) was derived by reverse transcription of RNA from human pe-
ripheral blood mononuclear cells (PBMC) followed by PCR. cDNA 
encoding amino acids 1-225 of human B7-2 was amplified using the 
oligonucleotides B7-2-sense 5'-AAAAGTCGACGCTAGCGCTGCT-
CCTCTG-3' and B7-2-antisense 5'-AAAACTCTAGAGATCTATC-
GATAGGAATGTGGTCTGG-3' which introduce Sail and Nhel re-
striction sites at the 5'-end and Clal, Bghl, and Xbal restriction sites 
at the 3'-end of the PCR product. 
The amplified B7-I208 and B7-2226 cDNA fragments were ligated in 
frame 5' to a synthetic sequence which encodes the Myc tag recog-
nized by the monoclonal antibody (Mab) 9E10 [19] and a cluster of 
6 histidine residues (His tag) in a modified pBluescript KS+ (Strata-
gene, Heidelberg, Germany). For expression in the yeast P. pastoris 
the B7-I208 and B7-2225 encoding fragments including Myc and His 
tags were isolated from the cloning vector and inserted into the yeast 
expression vector pPIC9 (Invitrogen) resulting in the piasmids pPIC9-
B7-I208 and pPIC9-B7-2 
225-
2.3. Construction of piasmids for the expression of the extracellular 
domain of human CTLA-4 
A cDNA fragment encoding the extracellular domain of human 
CTLA-4 (amino acid residues 1-125; referred to as CTLA-4125) was 
derived by PCR using CTLA-4-Ig cDNA (kindly provided by K. 
Pfeffer, Munich) as a template and the oligonucleotides CTLA-4-sense 
5'-TTTGTCGACGCTAGCGCAATGCACGTGGCC-3' and CTLA-
4-antisense 5'-TTTTCTAGACCATCCGAATCTGGG-3' which in-
troduce Sail and Nhel restriction sites at the 5'-end and an Xbal 
restriction site at the 3'-end of the PCR product. The amplified 
CTLA-4i25 cDNA fragment was fused to Myc and His tags and 
subcloned into the P. pastoris expression vector pPIC9 as described 
above resulting in the construct pPIC9-CTLA-4i25. CHO cells ex-
pressing the GPI-linked extracellular domain of human CTLA-4 on 
their surface were generated by introducing via PCR Hindlll and Spel 
restriction sites at the 5'- and 3'-ends of the respective CTLA-4 cDNA 
fragment (kindly provided by P. Dellabona and G. Casorati, Milan, 
Italy). The PCR product was ligated 5' to a DNA fragment encoding 
the GPI linker (123 bp fragment) of the human urokinase receptor 
[20] in the plasmid pRC/RSV. CHO cells were transfected with the 
construct using liposomal transfection (DOTAP, Boehringer Mann-
heim, Mannheim, Germany), stable transfectants were selected with 
G418 and tested for cell surface CTLA-4 expression with B7-1-Ig 
(kindly provided by P. Dellabona and G. Casorati). 
2.4. Expression in yeast and purification of recombinant proteins 
Derivatives of the pPIC9 expression vector were linearized by Sail 
digestion and used for transformation of P. pastoris GS115 cells by 
electroporation [21]. His4+/methanol-utilization+ (mut+) yeast colo-
nies were isolated on selection media following established protocols 
[22] and the phenotype of the resulting clones was confirmed by PCR 
using AOX1 5'- and 3'-primers (Invitrogen). 
For expression of recombinant proteins single yeast colonies were 
grown to an ODMo of 3 in BMGY medium, pH 7.5, the medium was 
exchanged with methanol-containing BMMY medium, pH 7.5, and 
protein expression was induced for 72 h at 30°C. Yeast cells were 
removed by centrifugation at 20000Xg. Supernatants containing 
soluble B7 and CTLA-4 proteins were passed through a 45 um filter, 
applied onto a Ni2+-saturated chelating sepharose column (Pharmacia 
Biotech, Freiburg, Germany) and the recombinant proteins specifi-
cally bound via their C-terminal polyhistidine tag were eluted with 
250 mM imidazole in PBS. Fractions containing the fusion protein 
were identified by SDS-PAGE and immunoblotting with Mab 9E10, 
pooled, concentrated by ultrafiltration, and dialyzed against PBS. 
Post-translational modification of recombinant proteins was analyzed 
in a deglycosylation reaction. 0.2 ug each of purified proteins were 
heated to 100°C for 10 min in PBS containing 0.1% SDS. Triton X-
100 was added to a final concentration of 1% and the proteins were 
incubated with 1 U of JV-glycosidase F (Boehringer Mannheim) for 
16 h at 37°C in a total reaction volume of 100 (il. 
2.5. Binding assays 
The binding of soluble B7-I208 and B7-2225 to the B7 counter-re-
ceptor CTLA-4 was determined by FACS analysis using CHO-CTLA-
4 cells. A single cell suspension was prepared by treatment with tryp-
sin, and 5x 105 CHO-CTLA-4 cells were incubated for 45 min at 4°C 
with 0.2-1 |ig each of B7-2225 or B7-I208 protein, followed by incuba-
tion with 3 |ig of Mab 9E10 and phycoerythrin-labeled goat anti-
mouse IgG (Rockland, Gilbertsville, PA) for 30 min. Binding of B7 
proteins was detected using a FACScan (Becton-Dickinson, Heidel-
berg, Germany). CHO cells served as a control. Similarly, the binding 
of soluble CTLA-4125 to B7-1 was determined by FACS analysis using 
B7-1 expressing THP-B7-1 cells, and parental B7-1-negative THP-1 
cells as a control. 
2.6. T cell proliferation assays 
Primary T cells were derived from the spleens of BALB/c mice 
exactly as described [23]. Flat bottom 96 well plates were coated over-
night with the mitogenic anti-mouse CD3 Mab 2C11 [24] (kindly 
provided by S. Desrivieres, Freiburg) alone or in combination with 
purified soluble B7-I208 or B7-2225- The plates were washed with PBS 
and 1 X 105 splenic T cells in RPMI medium supplemented with 8% 
FCS were added to each well. After incubation at 37°C for 60 h the 
cells were pulsed with 0.25 |iCi/well [3H]thymidine (DuPont, Boston, 
MA) for 12 h, the cultures were harvested, and the incorporation of 
[3H]thymidine was measured with a liquid scintillation counter (Beck-
man Instruments, Palo Alto, CA). 
3. Results 
3.1. Construction of piasmids for the expression in P. pastoris 
of the human costimulatory molecules B7-1 and B7-2, and 
the B7 counter receptor CTLA-4 
cDNAs encoding the extracellular domains of the human 
costimulatory molecules B7-I208. B7-2225, and the B7 counter-
receptor CTLA-4i25 were derived by polymerase chain reac-
tion with specific oligonucleotide primers. The respective 
cDNA fragments together with synthetic sequence tags at 
their 3'-ends were inserted into the yeast expression vector 
pPIC9. As shown in Fig. 1 the resulting piasmids pPIC9-B7-
I208, pPIC9-B7-2225, and pPIC9-CTLA-4i25 encode under the 
control of the methanol inducible alcohol oxidase 1 (AOX1) 
promoter fusion proteins consisting of an N-terminal cc-factor 
secretion signal from yeast, the extracellular domain of the 
respective human protein, and C-terminal Myc and polyhisti-
dine tags facilitating immunological detection with the mono-
clonal antibody (Mab) 9E10 [19] and purification via Ni2+ 





Fig. 1. Schematic representation of the expression cassettes in the 
yeast pPIC9 vector encoding CTLA-4i25, B7-I208, or B7-2225- Ex-
pression in the yeast P. pastoris is regulated by the alcohol oxidase 
promoter (AOX1) and is directed to the extracellular space via the 
yeast a-factor secretion signal (a). M, Myc tag; H, polyhistidine 
tag. 
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3.2. Expression and purification of CTLA-4ysi, B7-1208 and 
-87-2225 
P. pastoris GS115 cells which carry the pPIC9 expression 
constructs stably integrated into the genome were obtained by 
electroporation of competent cells with plasmids linearized by 
Sail digestion. Upon integration of the pPIC9 plasmids pos-
itive clones were identified by selection on minimal dextrose 
agar plates lacking histidine. The 5'- and 3'-sequences of the 
alcohol oxidase gene in the vector allow for integration into, 
and disruption of the genomic AOX1 locus, resulting in cells 
which grow very slowly in medium containing methanol as the 
only carbon source (mut8). Due to the presence of the intact 
HIS4 gene in pPIC9 vectors, the expression cassettes can al-
ternatively be integrated into the genomic HIS4 locus. The 
resulting cells grow normally with methanol as the only car-
bon source (mut+). The phenotype of clones was character-
A 
B 
Fig. 2. A: SDS-PAGE analysis of purified CTLA-4125 in the pres-
ence (lane 1) or absence (lane 2) of the reducing agent ß-mercapto-
ethanol (ß-MSH). The positions of monomeric and dimeric forms of 
the protein are indicated. Lanes 3 and 4, monoclonal antibody 9E10 
immunoblot analysis of purified CTLA-4i25 before (lane 3) or after 
(lane 4) treatment with protein iV-glycosidase F (N-Glyco). The po-
sitions of differently glycosylated forms of CTLA-4i25 and of molec-
ular weight standards are indicated. B: The binding of purified 
CTLA-4i25 to THP-B7-1 cells and B7-negative THP control cells 
was detected by F ACS analysis with monoclonal antibody 9E10 
and phycoerythrin-labeled goat anti-mouse IgG. 
ized by PCR using genomic DNA as a template and 5'- and 
3'-AOXl primers. Expression of recombinant proteins by 
mut+ clones was confirmed by immunoblot analysis of culture 
supernatants with Mab 9E10 (data not shown). 
Upon induction of expression in methanol-containing me-
dium, CTLA-4i25, B7-I208 and B7-2225 proteins were effi-
ciently secreted into the culture supernatant. Yeast cells 
were removed by centrifugation and the recombinant proteins 
were purified via Ni2+ affinity chromatography. SDS-PAGE 
analysis of the proteins revealed a purity of greater than 80% 
after a single round of purification (see below). The yield of 
soluble recombinant B7-I208 and B7-2225 proteins purified 
from 1 1 of yeast culture supernatant was typically 10 mg. 
The yield of soluble recombinant CTLA-4125 was even higher 
with approximately 15 mg from 1 1 of yeast culture. 
3.3. Soluble CTLA-4\2i, is expressed as a dimer and binds to 
B7 molecules 
Full-length CTLA-4 exists mainly as a disulfide-linked ho-
modimeric molecule on the surface of T cells. Likewise, yeast-
expressed soluble CTLA-4i25 was also found mainly in a di-
meric disulfide-linked form as analyzed by SDS-PAGE under 
reducing and non-reducing conditions (Fig. 2A, lanes 1 and 
2). In contrast to the calculated molecular weight of 17.1 kDa 
the protein migrates as a smear of bands with apparent mo-
lecular masses of approximately 26-32 kDa (monomeric 
CTLA-4125) and 35-50 kDa (dimeric CTLA-4125). iV-Glycosi-
dase F treatment of the protein reduced the apparent molec-
ular mass indicating that the higher molecular mass of yeast-
expressed CTLA-4125 protein is mainly due to post-transla-
tional modification by TV-linked glycosylation (Fig. 2A, lanes 
3 and 4). 
To investigate the functionality of soluble CTLA-4i25 the 
binding of the recombinant protein to B7-1 on the surface of 
cells was tested by FACS analysis. THP-B7-1 monocytoma 
cells stably transfected with B7-1 cDNA were incubated 
with CTLA-4125 and specifically bound protein was detected 
with Mab 9E10 and phycoerythrin-labeled goat anti-mouse 
IgG. The results are shown in Fig. 2B. Strong binding of 
CTLA-4i25 to THP-B7-1 cells but not to B7-negative parental 
THP cells could be detected indicating that yeast-expressed 
soluble CTLA4 is functionally active and interacts with B7. 
3.4. Characterization of soluble B7-l2m and B7-2225 
Soluble B7-I208 and B7-2225 proteins were produced as 
monomeric molecules as determined by SDS-PAGE under 
non-reducing conditions (data not shown). Like in the case 
of CTLA-4i25 the apparent molecular weight of the yeast-ex-
pressed B7 proteins was higher than their calculated molecular 
weight. B7-l2o8 (calculated MT of 28.5 kDa) and B7-2225 (cal-
culated MT of 30.2 kDa) migrate as several distinct bands or a 
smear of bands ranging from 60 to approximately 100 kDa 
(Fig. 3A,B, lane 1). N-Glycosidase F treatment reduced the 
apparent molecular mass of the proteins indicating that they 
are post-translationally modified by AMinked glycosylation 
(Fig. 3A,B, lanes 2 and 3). 
The binding of soluble B7-l2o8 and B7-2225 proteins to the 
B7 counter receptor CTLA-4 was tested by FACS analysis. 
CHO-CTLA-4 cells expressing GPI-linked CTLA-4 on their 
surface were incubated with B7-I208 or B7-2225 and specifically 
bound protein was detected with Mab 9E10 and phycoery-
thrin-labeled goat anti-mouse IgG. The results are shown in 
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Fig. 3. SDS-PAGE analysis of purified B7-l2os (A) and B7-2225 (B) under reducing conditions (lanes 1). The positions of B7-l2os and B7-2225 
are indicated. Lanes 2 and 3, monoclonal antibody 9E10 immunoblot analysis of purified B7 proteins before (lane 2) or after (lane 3) treatment 
with protein A'-glycosidase F (N-Glyco). The positions of differently glycosylated forms of B7-l2os and B7-2225, and of molecular weight stand-
ards are indicated. C: The binding of B7-I208 and B7-2225 to CHO-CTLA-4 cells or CTLA-4-negative CHO control cells was detected by 
FACS analysis with monoclonal antibody 9E10 and phycoerythrin-labeled goat anti-mouse IgG. 
Fig. 3C. Binding of both proteins, B7-I208 (left panel) and B7-
2225 (right panel) to CHO-CTLA-4 cells but not to CHO 
control cells could be detected. Incubation of CHO-CTLA-4 
cells with soluble B7 proteins in the presence of a 50-fold 
molar excess of soluble CTLA-4i25 blocked the binding of 
B7-I208 and B7-2225 which further confirmed the specificity 
of the interaction (data not shown). These results indicate 
that the yeast-expressed B7 proteins are functionally active 
and interact with B7 counter receptors. 
3.5. B7-I208 and B7-2225 enhance T cell proliferation 
It has been shown previously that a recombinant B7-1-Ig 
fusion protein enhanced T cell proliferation in combination 
with a mitogenic anti-CD3 antibody when it was immobilized 
on a plastic surface, but not as a soluble molecule [6]. In order 
to characterize the costimulatory activity of the B7-I208 and 
B7-2225 proteins, similar experiments were performed. The 
wells of 96 well plates were coated overnight with 1 |ig/ml 
of the mitogenic anti-CD3 Mab 2C11 [24] alone or in combi-
nation with increasing concentrations of 0.5-50 |J.g/ml of pu-
rified B7-l2o8- T cells isolated from the spleens of BALB/c 
mice were added to the wells, and proliferation of the cells 
was measured via the incorporation of [3H]thymidine. The 
results are shown in Fig. 4A. B7-I208 enhanced the prolifer-
ation of T cells in a dose-dependent manner. In a similar 
experiment using 1 |o.g/ml of anti-CD3 Mab and 0.5-50 jj.g/ 
ml of purified B7-2225, the B7-2 protein failed to provide a 
costimulatory signal for T cells (data not shown). However, 
when the anti-CD3 antibody was applied at a higher concen-
tration (5 |Xg/ml) both recombinant proteins B7-I208 and B7-
2225 were effective in enhancing T cell proliferation (Fig. 4B). 
In several independent experiments the costimulatory activity 
of immobilized B7-l2os was higher than that of B7-2225 result-
ing in a consistent 2-3-fold increase in T cell proliferation in 
comparison to cells treated only with anti-CD3 antibody. In 
contrast, B7-2225 led to a significant but only moderate en-
hancement of [3H]thymidine incorporation in T cells co-
treated with anti-CD3 Mab (Fig. 4B). 



































Fig. 4. Costimulation of primary T cells by B7-l2os and B7-222s. Splenic T cells from BALB/c mice were incubated with the indicated concen-
trations of immobilized anti-CD3 monoclonal antibody and purified B7-I208 (A, B) or B7-2225 (B). Proliferation of cells was measured by 
[3H]thymidine incorporation. Each value was determined in triplicate. The standard deviation is represented by error bars. 
4. Discussion 
Recombinant lymphocyte cell surface molecules have 
helped to study their biological function and to uncover their 
complex interactions with ligands and receptors. Nonetheless 
to date only few lymphocyte antigens have been produced in 
non-mammalian expression systems although the yield of re-
combinant protein from mammalian cells is usually low and 
protein purification is complicated. 
The yeast P. pastoris has proved to be a valuable tool for 
the expression of a wide variety of heterologous proteins [18]. 
However, data on the expression of lymphocyte cell surface 
molecules in yeast are still very limited. We have developed a 
P. pastoris expression system for the production of soluble 
forms of human B7-1 and B7-2 and their counter-receptor 
CTLA-4. Recombinant proteins comprising the respective ex-
tracellular domains were expressed at high levels and could be 
purified from culture supernatants following a simple one-step 
purification protocol. The yeast-produced molecules retained 
their functionality and specific binding to their natural coun-
terparts could be demonstrated by FACS analysis. In T cell 
proliferation assays costimulation of T cells by immobilized 
B7-I208 and B7-2225 in the presence of an anti-CD3 antibody 
was observed. In these experiments B7-I208 appeared to be 
superior in its activity to B7-2225- It has been demonstrated 
that B7-1 binds to CD28 or CTLA-4 with different kinetics 
than B7-2 [25] which might explain why B7-2225 in compar-
ison to B7-I208 is less efficient in enhancing T cell prolifera-
tion. 
We have also produced recombinant B7-I208 and B7-2225 
proteins in an E. coli expression system. However, in contrast 
to the molecules produced in yeast the bacterially expressed 
proteins failed to bind to the appropriate counter-receptor 
(data not shown). Although we cannot rule out that more 
sophisticated purification or refolding protocols would result 
in functionally active bacterial proteins, it is possible that 
glycosylation of B7-1 and B7-2 is a prerequisite for correct 
protein folding and efficient binding to their counter-recep-
tors. 
Endogenously expressed costimulatory molecules are highly 
glycosylated in their extracellular domains. Judged from the 
apparent molecular weight of CTLA-4i25, B7-I208. and B7-
2225 in SDS-PAGE the degree of glycosylation of P. pastoris 
expressed proteins and endogenously expressed mammalian 
costimulatory molecules appears to be similar [6-9]. Interest-
ingly, in contrast to yeast expressed B7-2 and CTLA-4 which 
like endogenous mammalian costimulatory molecules ap-
peared as a smear of bands in SDS-PAGE, the truncated 
B7-1 protein migrated as several distinct bands. This most 
likely illustrates differences in the type of glycosylation of 
the yeast expressed proteins. Due to such differences the re-
combinant proteins might be immunogenic in vivo. The addi-
tion of specific inhibitors to the growth medium or the use of 
yeast mutants which have a defect in their glycosylation ma-
chinery and glycosylate heterologous proteins to a much lower 
degree might help to overcome this potential problem [26]. 
Costimulation via the B7-CD28 pathway plays a crucial 
role in the activation of T helper cells and cytotoxic T cells. 
Both, enhancement or prevention of the costimulatory signal 
might be beneficial under different pathophysiological condi-
tions. Attempts have been made for example to increase the 
immunogenicity of tumor cells by providing them with B7 
molecules on their surface [27]. Systemic treatment of mice 
with soluble CTLA-4-Ig fusion protein expressed in COS cells 
resulted in a remarkable suppression of the T cell response, 
could prevent autoimmune disease, prolonged the survival of 
xenogeneic tissue grafts, and diminished graft versus host dis-
ease [11-13,28]. Soluble CTLA-4 expressed in P. pastoris 
might provide a novel source for large amounts of this potent 
immunosuppressive molecule. 
Here we have shown that biologically active, soluble lym-
phocyte receptors and their ligands can be produced at high 
yields in P. pastoris. Our data suggest that the yeast expres-
sion system could be a suitable alternative to expression of 
68 
costimulatory ligands and receptors in mammalian cells. The 
recombinant proteins obtained might be useful tools to inves-
tigate further the complex interactions of costimulatory li-
gands and receptors, and their role in T cell activation. 
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